Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow-up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.
for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow-up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.
| I N TR ODU C TI ON
Many patients with hemoglobinopathies have been infected with hepatitis C virus (HCV) through blood transfusion, mostly before screening of blood donors was introduced in 1992. In the years immediately after the HCV screening test became available, the prevalence of chronic HCV infection among patients with thalassemia ranged from 4% in Turkey to 85% in Italy. Although the prevalence of HCV infection has progressively decreased over the last 20 years, it is still higher than the general population. 1 Genotype 1b infection is the most frequent in
Italy. In epidemiological and cohort studies, the proportion of patients with genotype 1b infection often exceeds 50%. 
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untreated. [2] [3] [4] Cirrhosis has been reported in up to 32% of patients with thalassemia [5] [6] [7] [8] [9] ; these patients are at increased risk of death. 10 Presence of chronic HCV infection and the extent of iron overload are strong predictors of liver fibrosis progression. 5, 7, 11 Effective chelation therapy and treatment of HCV infection are needed in order to prevent liver complications and improve morbidity and mortality. 1, 7, 12 Pegylated interferon (peg-IFN) plus ribavirin (RBV) has been the standard of care for the treatment of chronic HCV infection and cirrhosis. 13 Studies of peg-IFN plus RBV have demonstrated sustained virological response (SVR) rates of 25 2 64% in patients with thalassemia and HCV infection. [14] [15] [16] [17] However, peg-IFN and RBV are both associated with anemia. 13, 15, 18 The addition of RBV to peg-IFN significantly increases the rate of SVR; however, in patients with thalassemia, RBV-associated hemolysis leads to an increased requirement for blood transfusions, which in turn can lead to worsening of iron overload. The aim of this study was to evaluate the safety and efficacy of DAA regimens in patients with hemoglobinopathies and chronic HCV liver disease treated in Italy.
| M E TH ODS

| Study design
Patients with hemoglobinopathies and HCV chronic disease from 11 thalassemia centers and who were treated with DAA regimens according to the Italian Medicines Agency guidelines 25 were included in the "THAlassemia and hepatitis C Advance -Societ a Italiana Talassemie ed
Emoglobinopatie" (ITHACA-SITE) dataset. The chart review was approved by the Independent Ethics Committee at each participating center, with the coordinating committee being located in Genoa, Italy.
All patients signed an informed consent to record their clinical and virological data in the database.
In the database, data were collected at baseline, at 4 weeks of therapy, at the end of treatment and at 12 weeks of follow-up. Data collected included levels of aspartate transaminase (AST), alanine transaminase (ALT), serum creatinine, and quantitative serum HCV RNA.
Serum ferritin levels were evaluated at baseline and at 12 weeks of follow-up after the end of therapy. Clinical data regarding diabetes, kidney disease, heart disease, hypogonadotropic hypogonadism, hypothyr- 
| Patients
Patients included in the study had hemoglobinopathies with chronic hepatitis due to HCV and the presence of fibrosis (defined as 
| Endpoints and outcomes measured
The primary endpoints of the study were to evaluate the efficacy and safety of DAAs in patients with hemoglobinopathies and chronic hepatitis or cirrhosis due to HCV.
Outcomes measured included the SVR rate (i.e., the proportion of patients with negative HCV RNA at week 12 of post-treatment follow up), and the effect of treatment on liver enzymes (changes from baseline in ALT, AST, and serum ferritin levels at the end of treatment and at week 12 of follow up). Baseline was defined as within the 30 days prior to receiving DAAs, and end of treatment was defined as 12 weeks after initiation of treatment. Follow up was conducted 12 weeks after the end of treatment (12-week follow up). Liver MRI-T2* evaluations were performed within 6 months of commencement of therapy.
| Statistical analysis
Descriptive statistics were summarized as means 6 standard deviation (SD), medians, and percentages. To show the distribution of levels of ALT, AST, and ferritin at baseline, at the end of the treatment, and at 12 weeks of follow up, boxplot graphs were used. The Shapiro-Wilk test was used to test the normality of distributions. Changes in baseline levels of ALT, AST, and ferritin were compared at the end of treatment and/or after 12 weeks of follow up using the paired Wilcoxon test. The
Wilcoxon test (unpaired) was also used to compare ferritin measurements between treated patients and the control group. Data were manipulated using Excel (Microsoft, Seattle, WA, USA), and statistical computing and graphics analyses were conducted using R software. (24%) had mild iron overload and 6 patients (12%) had MRI-T2* measurements corresponding to moderate or severe liver iron overload.
The control group comprised 39 patients with thalassemia major.
The mean age (6SD) of the control group was 35 (69) years and the majority was female (n 5 25). All controls were HCV-RNA negative and without iron overload (MRI-T2* >6.3 ms), with a mean ferritin level of 676 (6554) ng/mL (range 125-2537 ng/mL). The follow-up of the control group is greater than 24 months. Table S1 .
| Treatments
Chelation therapy was changed to deferoxamine in 41 (29%) patients based on the previous studies of peg-IFN, 1 which reported that oral chelation therapy with deferoxamine was recommended for patients at risk of leucopenia and some physicians preferred treatment with deferoxamine as a precaution due to the lack of drug interaction data available. Iron chelation therapy was not prescribed in one patient with thalassemia major who had undergone allogeneic bone marrow transplantation and in patients affected by other hemoglobinopathies.
Patients received a wide range of concurrent therapies during the study. A description of concurrent therapies received by patients during anti-HCV treatment (other than chelation therapy) can be found in the Supporting Information Figure S1 and Table S2 .
| Efficacy and safety
By intention-to-treat analysis, 136 patients (97.8%) achieved a response at end of treatment, and 130 (93.5%) achieved a SVR. In addition to the three patients who died during therapy or follow-up, six patients did not achieve HCV clearance. Five patients (one treated with SOF plus SMV, one treated with SOF plus DCV and three treated with SOF plus LDV) achieved virological response at the end of therapy and experienced relapses during the 12-week follow-up, one of these six patients did not achieve virological response on treatment with OBV/ PTV plus DBV and at the end of the therapy had an HCV-RNA serum level of 20 IU/mL. These patients had increased levels of HCV-RNA during the follow up. All of these patients were treated for 12 weeks without RBV. SVR rates were high regardless of iron chelation therapy. HCV, hepatitis C virus; MRI, magnetic resonance imaging; peg-IFN, pegylated interferon; SD, standard deviation.
ORIGA ET AL.
AJH AJH Three patients died during treatment of causes unrelated to therapy. A 59-year-old woman with sickle-cell anemia and a history of anemia due to hematological disease died after 5 days of therapy with SOF plus SMV due to a hemolytic crisis followed by heart failure and cardiac shock. This death was unlikely to be related to treatment, as hemolytic anemia has not been reported in the literature with either of these antiviral drugs. A 36-year-old man with major thalassemia, diabetes, hypothyroidism, hypogonadism and severe heart disease died from secondary heart failure following bacterial sepsis. Finally, a 40-year-old man with Child-Pugh C cirrhosis died 4 weeks after the end of antiviral therapy died from liver failure after the appearance of a hepato-renal syndrome. Also, no interference with chelation therapy was observed, and no patients discontinued chelation therapy.
At the start of DAA treatment, only 29.2% of patients had normal serum ALT, while 86.7% and 92% had normal ALT at the end of treatment and 12 weeks thereafter, respectively. Reductions in serum ALT levels from baseline were statistically significant both at the end of treatment (P < .001) and at week 12 of follow up (P < .001; Figure 2 ).
At baseline the mean (6SD) value of serum ferritin was 1450 (61660) ng/mL (range: 103 2 11,190 ng/mL). The mean (6SD) value of serum ferritin at the 12-week follow up after the end of treatment was 1080 (61144) ng/mL (range: 88 2 5696 ng/mL) among patients who were HCV-RNA negative at Week 12 of treatment and the mean reduction from baseline to Week 12 was statistically significant (433 ng/mL, P < .001; Supporting Information Figure S2 ).
In the comparison of treated patients and the control group of patients without HCV infection and iron overload, mean baseline ferritin levels were significantly higher in the treated versus control group (mean difference: 773 ng/mL; P5.002), whereas at the 12-week follow 
| D I SCUSSION
This is the largest observational study of DAAs in patients with hemoglobinopathies and HCV infection published to date. Until April 2017 in Italy, the use of DAA-based regimens was restricted to patients with advanced liver fibrosis or HCV-related severe extra-hepatic manifestations. Nevertheless, DAAs appeared to be safe and effective in this patient population in the current study. Patients showed high treatment response rates (SVR 93.5%), which were similar to those reported in patients without hemoglobinopathies. 3, 19, 20 Moreover, in our patient cohort, no treatment-related adverse events responsible for premature discontinuations were observed, and no overt drug-drug interactions between iron chelators and antivirals were reported. The three deaths that occurred during the observational period were due to complications of hematological or liver disease and not related to DAA therapy.
As expected, patients showed a significant reduction in serum liver enzymes and ferritin. Moreover, ferritin levels in the treated patients at the follow up 12 weeks after the end of DAA therapy were not significantly different from those in the control group of patients with thalassemia without HCV infection or iron overload.
Our data confirm the finding of the multicenter phase III randomized trial of immediate or deferred treatment with elbasvir (EBR) plus grazoprevir (GRZ) in 159 patients with HCV infection and inherited blood disorders. 22 In that study, patients with thalassemia, sickle cell anemia, hemophilia A/B or von Willebrand disease were enrolled in 31 centers worldwide (US, Europe, Australia, Canada, Israel, and Thailand) and treated with a 12-week course of EBR plus GRZ. Among 107 patients who received immediate treatment, an SVR was achieved by 93.5% of the patients. The rate of serious adverse events unrelated to anti-HCV therapy was higher in patients who deferred treatment than in those who received immediate treatment (11.5% vs. 2.8%), suggesting an advantage of earlier treatment in these subjects. 22 Higher SVR rates were reported in a smaller retrospective study of 81 patients with hemoglobinopathies (b-thalassemia major 86%, sickle cell anemia/b-thalassemia 14%) and HCV infection (38%) treated at a single institution in Greece between 2000 and 2015. 21 In that study, 11 patients received treatment with DAAs. Nine of them had failed a previous IFN-based course, and seven had severe fibrosis. All patients achieved SVR, and ferritin levels appeared to be reduced in most patients after treatment versus baseline.
Finally, in two case studies 23, 24 two patients with hemoglobinopathies were successfully cured with SOF-based regimens. In the first case study, a 51-year-old female patient with HbS b 0-thalassemia was treated with SOF plus SMV, and achieved liver enzyme normalization, without any signs of hemolysis or need for blood transfusion. 24 In the second case study, a 16-year-old male affected by sickle thalassemia received 12 weeks' of SOF plus PegIFN. 23 During the IFN-era, patients with hemoglobinopathies and HCV infection have largely been considered a "difficult-to-treat" population, due to the coexistence of liver iron overload, often associated with more advanced liver disease. The low response rates to IFN-based regimens have also led to patients with thalassemia being perceived as "difficult to cure," even with the newest DAA-based anti-HCV regimens. 21 In our study, the significant reduction of liver enzymes and ferritin associated with HCV elimination is clinically relevant, because they are two confounding factors in the management of patients with hematological disease. The levels of ferritin were reduced to those observed in a control group after HCV clearance. This may be due to the higher chelating efficacy of drugs in the liver that is not affected by inflammation. This finding confirms that ferritin is a more reliable marker in the monitoring of liver iron overload in patients without HCV infection.
Long-term measurements of serum ferritin and of the liver and heart iron overload by MRI is needed to confirm this hypothesis. The continuation of iron chelation therapy during treatment with DAAs contributed to the reduction of ferritin. Most of our cohort of patients was infected with HCV before the 1990s, hence the higher mean age in the treated group of patients than in the control group. However, mean serum ferritin levels after treatment with DAAs were similar to the younger control group. These results add further support to EASL guidelines recommending the use of DAAs in selected patients with comorbidities, with careful monitoring for drug-drug interactions. 13 The high number of enrolled patients, all followed for at least 3 months, is a particular strength of the study; it represents the largest observational population studied to date in this setting. However, the observational design is an obvious limitation of the current study.
Still, the use of RBV in patients with hemoglobinopathies infected with HCV requiring complex oral combination therapy continues to represent a treatment challenge since it is associated with a nonnegligible risk of hemolityc anemia, with increases in both ferritin values and the need for blood transfusions. However, the availability of RBV-free regimens will further simplify the clinical management of this subgroup of patients. 
